Medicine
Simulect 10 mg/2.5 mL powder for injection
Simulect 10 mg/2.5 mL powder for injection is a prescription medicine containing Basiliximab for intravenous use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store lyophilized Simulect under refrigerated conditions at 2ºC to 8ºC (36ºF…
Key facts
- Active ingredient (INN)
- Basiliximab
- Brand
- Simulect
- Strength
- 10 mg/2.5 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store lyophilized Simulect under refrigerated conditions at 2ºC to 8ºC (36ºF to 46ºF).
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC02 Basiliximab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 May 1998
- Identifiers
- RxCUI 1656643, 1656646, 1656648 +1DailyMed set ID 1af01887-b69d-444b-91ed-ebfe12784440NDC 0078-0331, 0078-0393Application BLA103764
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-use in 1 carton / 5 mL in 1 vial, single-use | 0078-0331-84 | Novartis Pharmaceuticals | 12 May 1998 |
| 1 vial, single-use in 1 carton / 2.5 mL in 1 vial, single-use | 0078-0393-61 | Novartis Pharmaceuticals | 12 May 1998 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Basiliximab is an interleukin-2 receptor blocking antibody indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine, USP (MODIFIED), and corticosteroids. MedsAcross supplies Basiliximab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BasiliximabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Simulect prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Simulect: European public assessment report (EPAR) · European Medicines Agency
Need Simulect 10 mg/2.5 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.